BRIEF published on 09/18/2024 at 07:05, 1 year 7 months ago Relief Therapeutics Completes Clinical Phase of RLF-OD032 Study Clinical Study Bioavailability RLF-OD032 Phenylketonuria Sapropterin Dihydrochloride
PRESS RELEASE published on 09/18/2024 at 07:00, 1 year 7 months ago Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 Relief Therapeutics completes clinical phase in RLF-OD032 proof-of-concept study for PKU treatment, expecting topline results in October 2024 Relief Therapeutics RLF-OD032 Proof-of-Concept Study PKU Treatment Topline Results
BRIEF published on 09/02/2024 at 07:05, 1 year 7 months ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
PRESS RELEASE published on 09/02/2024 at 07:00, 1 year 7 months ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Relief Therapeutics announces interim results of PKU GOLIKE study at SSIEM 2024, showing potential benefits for phenylketonuria patients. Study evaluates overnight Phe fluctuations Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
BRIEF published on 08/30/2024 at 07:05, 1 year 8 months ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Corporate Update Financial Results Revenue Increase Clinical Trials Corporate Update Cash Reserves
PRESS RELEASE published on 08/30/2024 at 07:00, 1 year 8 months ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports half-year 2024 financial results and provides corporate update, showcasing operational progress, key development programs, and financial stability Half-year Results Relief Therapeutics Financial Update Development Programs Cash Reserves
BRIEF published on 08/05/2024 at 07:05, 1 year 8 months ago Relief Therapeutics Secures Up to $11 Million from Royalty Sales FDA Approval Clinical Development Relief Therapeutics Non-dilutive Funding Royalty Sales
PRESS RELEASE published on 08/05/2024 at 07:00, 1 year 8 months ago Relief Therapeutics Secures up to $11 Million from Royalty Sales Relief Therapeutics secures $11 million from royalty sales for RLF-TD011 clinical development and pipeline advancement. Funding from SWK Holdings Corporation to support rare disease treatment options SWK Holdings Corporation Clinical Development Relief Therapeutics Rare Diseases Royalty Sales
BRIEF published on 06/27/2024 at 12:50, 1 year 10 months ago Relief Therapeutics Holding SA Reports Results of Annual General Meeting Board Of Directors Shareholders Financial Statements Relief Therapeutics AGM Results
PRESS RELEASE published on 06/27/2024 at 12:45, 1 year 10 months ago RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting RELIEF THERAPEUTICS Holding SA announces the results of its Annual General Meeting of Shareholders in Geneva. Details on approved resolutions and election outcomes Annual General Meeting Shareholders Resolutions RELIEF THERAPEUTICS Holding SA Geneva
Published on 05/01/2026 at 22:30, 25 minutes ago Integrated Rewards Achieves SOC 2 Compliance to Support Enterprise-Scale Growth Across Canada's Card-Linked Rewards Network as EQ Closes Convertible Debt Financing
Published on 05/01/2026 at 22:30, 25 minutes ago Apex Critical Metals Announces Extension of Marketing Agreement with Rumble Strip Media Inc.
Published on 05/01/2026 at 18:00, 4 hours 55 minutes ago Star Copper to Present at the Emerging Growth Conference on May 7, 2026
Published on 05/01/2026 at 15:35, 7 hours 20 minutes ago LNG Energy Group Announces Partial Revocation of Cease Trade Order and Proposed Private Placement
Published on 05/01/2026 at 19:23, 3 hours 32 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/01/2026 at 17:45, 5 hours 10 minutes ago Burkhalter Group acquires Progressio Holding GmbH and anplaq ag, Tamins (GR)
Published on 05/01/2026 at 17:21, 5 hours 34 minutes ago Fuller, Smith & Turner PLC: Total Voting Rights and Treasury Shares
Published on 04/30/2026 at 20:00, 1 day 2 hours ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 1 day 3 hours ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 1 day 3 hours ago Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 1 day 4 hours ago Minutes of the Combined General Meeting held on April 30, 2026
